Saroglitazar

Name: Saroglitazar in Primary biliary cholangitis: Economic impact of Primary biliary cholangitis on families
Published: 2026-09-14T15:39:06-04:00

Primary biliary cholangitis

Manufacturer: Zydus Therapeutics
Regulatory submission: NDA submitted by May 2026
Launch: Anticipated in April 2027, the start of Zydus fiscal year 2028
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description Burden of Primary biliary cholangitis

Economic impact of Primary biliary cholangitis on families

1 evidence topic · 1 source

Modeled informal-caregiver productivity losses

“Approximately 6.4% of the societal and 8.1% of the fiscal consequences related to caregiver productivity losses.” (opens the source at this quote in a new tab)